Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance

Journal of Acquired Immune Deficiency Syndromes

Volumn 4, Issue 6, 1991, Pages S42-S46

  Drew, W Lawrence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; CMV retinitis; Cytomegalovirus infection; Ganciclovir resistance; HIV

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CONFERENCE PAPER; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; RETINITIS;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MICROBIAL; GANCICLOVIR; HIV INFECTIONS; HUMAN;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0025997468     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320:289-93.
2. Coen DM, Schaffer PA. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sei USA 1980; 77:2265-9.
3. Schnipper LE, Crumpacker CS. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Nail Acad Sci USA 1980; 77:2270-3.
4. Darby G, Field HJ, Salisbury SA. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature 1981; 289:81-3.
5. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 343:1731-4.
6. Armstrong D, Gold JWM, Dryjanski J, et al. Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103:738-43.
7. Drew WL, Mintz L, Miner RC, Sands M, Ketterer B. Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 1981; 143:188-92.
8. Drew WL. Cytomegalovirus infection in patients with AIDS. J Infect Dis 1988; 158:449-56.
9. Reichert CM, O’ Leary TJ, Levens DL, Simrell CR, Macher AM. Autopsy pathology in the acquired immune deficiency syndrome. Am J Palhol 1983; 112:357-82.
10. Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acq Immun Def Synd 1991; 4(suppl 1):S29-35 (this issue).
11. Verheyden JPH. Evolution of therapy for cytomegalovirus infection. Rev Infect Dis 1988; 10(suppl 3):S477-89.
12. Smee DF, Boehme R, Chernow M, Binko BP, Matthews TR. Intracellular metabolism and enzymatic phosphorylation of 9-(l, 3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol 1985; 34:1049-56.
13. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988; 10(suppl 3):S490-4.
14. Drew WL, Buhles W, Dworkin RJ, Erlich KS. Management of herpes virus infections (CMV, HSV, VZV). In: Sande MA, Volberding PA, eds. The medical management of AIDS, 2nd edition. Philadelphia: W. B. Saunders, 1990:316-38.
15. Cantrill HL, Henry K, Melroe NH, Knobloch WH, Ramsay RC, Balfour HH Jr. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 1989; 96:367-74.
16. Buhles WC Jr, Mastre BJ, Tinker AJ, Strand V, Koretz SH, the Syntex Collaborative Ganciclovir Treatment Study Group. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988; 10(suppl 3):S495-506.
17. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 1977; 74:5716-20.
18. Furman PA, St. Clair MH, Fyfe JA, Rideout JL, Keller PM, Elion GB. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol 1979; 32:72-7.
19. Derse D, Cheng Y-C, Furman PA, St. Clair MH, Elion GB. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate: effects on primer-template function. J Biol Chem 1981; 256:11447-51.
20. Drew L, Matthews T, Freitas V, Miner RC, Blair M, Buhles W. Lack of CMV resistance to DHPG (ganciclovir) (abstract 1098). In: Program and abstracts of the Twenty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology, 1987:288.
21. Biron KK, Fyfe JA, Stanat SC, et al. A human cytomegalovirus mutant resistant to the nucleoside analog 9-[2-hydroxy-1 -(hydroxymethyl)ethoxy]methyl guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci USA 1986; 83:8769-73.
22. Biron KK, Stanat SC, Reardon J, Erice A, Balfour H, Jordan MC. Ganciclovir-resistant clinical isolates of CMV: antiviral susceptibility profiles and mode of resistance studies [Abstract]. In: Abstracts of the papers presented at the Second International Cytomegalovirus Workshop. San Diego: University of California, 1989:65.
23. Walmsley SL, Chew E, Read SE, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis 1988; 157:569-72.
24. Parenti DM, Drew WL, Feinberg JE, et al. Treatment of ganciclovir (GCV) resistant cytomegalovirus (CMV) retinitis with foscarnet (PFA). Abstract Th-B. 437, presented at the 6th International Conference on AIDS, San Francisco, 1990.